本帖最后由 老马 于 2012-1-13 21:20 编辑 7 ?9 U2 x( q( E6 m
2 r! Q/ S5 ^" t* |2 i; W
爱必妥和阿瓦斯丁的比较
' q2 H1 j0 Q" @* z
* ]9 U* }) e2 |# h0 N% N$ q
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 e. W: o% Y" `$ F' X- D9 b
4 w: V& c% G: G0 V, j7 H; `
; I8 P/ U7 |- T, X
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/, n+ {. Q0 R$ i# K, M7 E
==================================================
: I8 \8 G7 r, ^: K1 o FOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) g3 J3 ^4 |3 a/ L. |Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.3 m& j8 g( g$ a
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 ?8 Y) h) W' S1 G! [: w; w: I5 A
|